FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982410050> ?p ?o ?g. }

• W2982410050 abstract "Abstract Background Multiple daily subcutaneous injections (MDSIs) are mainly used for formulating an insulin therapy for diabetic patients; however, they also cause insulin-derived amyloidosis (IDA) and lead to poor glycemic control. In addition, for the continuous subcutaneous insulin infusion system (CSII), precipitation frequently causes catheter occlusion and, if the precipitate in the formulations is amyloid, the injection of the insoluble amyloid into the subcutaneous tissue leads to IDA. The aim of this study was to conduct in vitro experiments and present a situation where insulin formulations cause precipitation and amyloid formation. Methods Humulin®R and NovoRapid® were used as model formulations for MDSIs and CSII, respectively. The generation of the precipitation was evaluated by measuring turbidity, and amyloid formation was evaluated by using Thioflavin T. Humulin®R was mixed with saline buffer solutions and glucose solutions to evaluate the effect of dilution. In addition, we created an experimental system to consider the effect of the time course of condition changes, and investigated the effects of insulin concentration, m -cresol existence, and pH change on the generation of the precipitate and amyloid in the formulation. Results In both the original and diluted formulations, physical stimulation resulted in the formation of a precipitate, which in most cases was an amyloid. The amyloid was likely to be formed at a near neutral pH. On the contrary, although a precipitate formed when the pH was decreased to near the isoelectric point, this precipitate was not an amyloid. Further decreases in pH resulted in the formation of amyloids, suggesting that both the positive and negative charged states of insulin tended to form amyloids. The formulation additive m -cresol suppressed amyloid formation. When additives were removed from the formulation, the amyloid-containing gel was formed in the field of substance exchange. Conclusions To consider changes in conditions that may occur for insulin formulations, the relationship between the formation of precipitates and amyloids was demonstrated in vitro by using insulin formulations. From the in vitro study, m -cresol was shown to have an inhibitory effect on amyloid formation." @default.
• W2982410050 created "2019-11-08" @default.
• W2982410050 creator A5026592197 @default.
• W2982410050 creator A5028189009 @default.
• W2982410050 creator A5029067127 @default.
• W2982410050 creator A5068523895 @default.
• W2982410050 creator A5072835938 @default.
• W2982410050 creator A5075205053 @default.
• W2982410050 creator A5075946896 @default.
• W2982410050 creator A5087864344 @default.
• W2982410050 date "2019-10-30" @default.
• W2982410050 modified "2023-10-14" @default.
• W2982410050 title "Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations" @default.
• W2982410050 cites W123869245 @default.
• W2982410050 cites W1570483440 @default.
• W2982410050 cites W1720271623 @default.
• W2982410050 cites W1967655470 @default.
• W2982410050 cites W1974187431 @default.
• W2982410050 cites W1981638035 @default.
• W2982410050 cites W1992885480 @default.
• W2982410050 cites W2002371885 @default.
• W2982410050 cites W2007166916 @default.
• W2982410050 cites W2015204917 @default.
• W2982410050 cites W2034376929 @default.
• W2982410050 cites W2043761562 @default.
• W2982410050 cites W2087383537 @default.
• W2982410050 cites W2106956914 @default.
• W2982410050 cites W2126888693 @default.
• W2982410050 cites W2136783088 @default.
• W2982410050 cites W2164818290 @default.
• W2982410050 cites W2329729814 @default.
• W2982410050 cites W2346757956 @default.
• W2982410050 cites W2410867099 @default.
• W2982410050 cites W2753304029 @default.
• W2982410050 cites W2778675863 @default.
• W2982410050 cites W2397622534 @default.
• W2982410050 doi "https://doi.org/10.1186/s40780-019-0151-5" @default.
• W2982410050 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6820959" @default.
• W2982410050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31687164" @default.
• W2982410050 hasPublicationYear "2019" @default.
• W2982410050 type Work @default.
• W2982410050 sameAs 2982410050 @default.
• W2982410050 citedByCount "11" @default.
• W2982410050 countsByYear W29824100502020 @default.
• W2982410050 countsByYear W29824100502021 @default.
• W2982410050 countsByYear W29824100502022 @default.
• W2982410050 countsByYear W29824100502023 @default.
• W2982410050 crossrefType "journal-article" @default.
• W2982410050 hasAuthorship W2982410050A5026592197 @default.
• W2982410050 hasAuthorship W2982410050A5028189009 @default.
• W2982410050 hasAuthorship W2982410050A5029067127 @default.
• W2982410050 hasAuthorship W2982410050A5068523895 @default.
• W2982410050 hasAuthorship W2982410050A5072835938 @default.
• W2982410050 hasAuthorship W2982410050A5075205053 @default.
• W2982410050 hasAuthorship W2982410050A5075946896 @default.
• W2982410050 hasAuthorship W2982410050A5087864344 @default.
• W2982410050 hasBestOaLocation W29824100501 @default.
• W2982410050 hasConcept C107054158 @default.
• W2982410050 hasConcept C121332964 @default.
• W2982410050 hasConcept C126322002 @default.
• W2982410050 hasConcept C134018914 @default.
• W2982410050 hasConcept C142724271 @default.
• W2982410050 hasConcept C153294291 @default.
• W2982410050 hasConcept C165220095 @default.
• W2982410050 hasConcept C181199279 @default.
• W2982410050 hasConcept C185592680 @default.
• W2982410050 hasConcept C2776390293 @default.
• W2982410050 hasConcept C2777633098 @default.
• W2982410050 hasConcept C2778896982 @default.
• W2982410050 hasConcept C2779134260 @default.
• W2982410050 hasConcept C2779306644 @default.
• W2982410050 hasConcept C2779951007 @default.
• W2982410050 hasConcept C2780705028 @default.
• W2982410050 hasConcept C43617362 @default.
• W2982410050 hasConcept C502032728 @default.
• W2982410050 hasConcept C55493867 @default.
• W2982410050 hasConcept C71924100 @default.
• W2982410050 hasConcept C96294017 @default.
• W2982410050 hasConcept C98274493 @default.
• W2982410050 hasConceptScore W2982410050C107054158 @default.
• W2982410050 hasConceptScore W2982410050C121332964 @default.
• W2982410050 hasConceptScore W2982410050C126322002 @default.
• W2982410050 hasConceptScore W2982410050C134018914 @default.
• W2982410050 hasConceptScore W2982410050C142724271 @default.
• W2982410050 hasConceptScore W2982410050C153294291 @default.
• W2982410050 hasConceptScore W2982410050C165220095 @default.
• W2982410050 hasConceptScore W2982410050C181199279 @default.
• W2982410050 hasConceptScore W2982410050C185592680 @default.
• W2982410050 hasConceptScore W2982410050C2776390293 @default.
• W2982410050 hasConceptScore W2982410050C2777633098 @default.
• W2982410050 hasConceptScore W2982410050C2778896982 @default.
• W2982410050 hasConceptScore W2982410050C2779134260 @default.
• W2982410050 hasConceptScore W2982410050C2779306644 @default.
• W2982410050 hasConceptScore W2982410050C2779951007 @default.
• W2982410050 hasConceptScore W2982410050C2780705028 @default.
• W2982410050 hasConceptScore W2982410050C43617362 @default.
• W2982410050 hasConceptScore W2982410050C502032728 @default.
• W2982410050 hasConceptScore W2982410050C55493867 @default.
• W2982410050 hasConceptScore W2982410050C71924100 @default.
• W2982410050 hasConceptScore W2982410050C96294017 @default.

• next